Cargando…

Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans

PURPOSE: The objective of this study was to identify the trajectories that patients take after initiating long-term opioid therapy (LTOT). MATERIALS AND METHODS: Using a retrospective cohort design, veterans with chronic non-cancer pain (CNCP) initiating LTOT were identified. Group-based trajectory...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayes, Corey J, Gressler, Laura E, Hu, Bo, Jones, Bobby L, Williams, J Silas, Martin, Bradley C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214015/
https://www.ncbi.nlm.nih.gov/pubmed/34163232
http://dx.doi.org/10.2147/JPR.S308196
_version_ 1783709971906560000
author Hayes, Corey J
Gressler, Laura E
Hu, Bo
Jones, Bobby L
Williams, J Silas
Martin, Bradley C
author_facet Hayes, Corey J
Gressler, Laura E
Hu, Bo
Jones, Bobby L
Williams, J Silas
Martin, Bradley C
author_sort Hayes, Corey J
collection PubMed
description PURPOSE: The objective of this study was to identify the trajectories that patients take after initiating long-term opioid therapy (LTOT). MATERIALS AND METHODS: Using a retrospective cohort design, veterans with chronic non-cancer pain (CNCP) initiating LTOT were identified. Group-based trajectory models were used to identify opioid therapy trajectories based on days of opioid supply (primary outcome) and average daily morphine milligram equivalent dose (AMME; secondary outcome) in each 180-day period following initiation of LTOT. RESULTS: A total of 438,398 veterans with CNCP initiated LTOT. Nine trajectories were identified: 33.7% with persistent, high days covered, 17.7% with persistent, moderate days covered, 16.6% with slow, persistent days-covered reduction, 2.4% with days-covered reduction followed by increase, 4.6% with delayed days-covered reduction, 4.1% with rapid days-covered reduction, 10.9% with moderate-paced discontinuation, 3.4% with delayed discontinuation, and 6.5% with rapid discontinuation. Patients following discontinuation trajectories were more likely to be younger, persons of color, use more supportive services (eg, physical therapy), and received less opioid days’ supply and lower doses prior to initiating LTOT as compared to patients following persistent opioid days-covered trajectories. AMME trajectories were similar to days-covered trajectories. CONCLUSION: Among persons initiating LTOT, nine opioid trajectories emerged which can be broadly characterized into three main trajectory groups: persistent opioid therapy (2 trajectories), reductions in opioid therapy (4 trajectories), and discontinuation (3 trajectories). A majority of patients (51.4%) maintained persistent opioid therapy. Further research is needed to assess the risks of opioid-related adverse outcomes among the identified trajectories.
format Online
Article
Text
id pubmed-8214015
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82140152021-06-22 Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans Hayes, Corey J Gressler, Laura E Hu, Bo Jones, Bobby L Williams, J Silas Martin, Bradley C J Pain Res Original Research PURPOSE: The objective of this study was to identify the trajectories that patients take after initiating long-term opioid therapy (LTOT). MATERIALS AND METHODS: Using a retrospective cohort design, veterans with chronic non-cancer pain (CNCP) initiating LTOT were identified. Group-based trajectory models were used to identify opioid therapy trajectories based on days of opioid supply (primary outcome) and average daily morphine milligram equivalent dose (AMME; secondary outcome) in each 180-day period following initiation of LTOT. RESULTS: A total of 438,398 veterans with CNCP initiated LTOT. Nine trajectories were identified: 33.7% with persistent, high days covered, 17.7% with persistent, moderate days covered, 16.6% with slow, persistent days-covered reduction, 2.4% with days-covered reduction followed by increase, 4.6% with delayed days-covered reduction, 4.1% with rapid days-covered reduction, 10.9% with moderate-paced discontinuation, 3.4% with delayed discontinuation, and 6.5% with rapid discontinuation. Patients following discontinuation trajectories were more likely to be younger, persons of color, use more supportive services (eg, physical therapy), and received less opioid days’ supply and lower doses prior to initiating LTOT as compared to patients following persistent opioid days-covered trajectories. AMME trajectories were similar to days-covered trajectories. CONCLUSION: Among persons initiating LTOT, nine opioid trajectories emerged which can be broadly characterized into three main trajectory groups: persistent opioid therapy (2 trajectories), reductions in opioid therapy (4 trajectories), and discontinuation (3 trajectories). A majority of patients (51.4%) maintained persistent opioid therapy. Further research is needed to assess the risks of opioid-related adverse outcomes among the identified trajectories. Dove 2021-06-14 /pmc/articles/PMC8214015/ /pubmed/34163232 http://dx.doi.org/10.2147/JPR.S308196 Text en © 2021 Hayes et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hayes, Corey J
Gressler, Laura E
Hu, Bo
Jones, Bobby L
Williams, J Silas
Martin, Bradley C
Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans
title Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans
title_full Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans
title_fullStr Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans
title_full_unstemmed Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans
title_short Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans
title_sort trajectories of opioid coverage after long-term opioid therapy initiation among a national cohort of us veterans
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214015/
https://www.ncbi.nlm.nih.gov/pubmed/34163232
http://dx.doi.org/10.2147/JPR.S308196
work_keys_str_mv AT hayescoreyj trajectoriesofopioidcoverageafterlongtermopioidtherapyinitiationamonganationalcohortofusveterans
AT gresslerlaurae trajectoriesofopioidcoverageafterlongtermopioidtherapyinitiationamonganationalcohortofusveterans
AT hubo trajectoriesofopioidcoverageafterlongtermopioidtherapyinitiationamonganationalcohortofusveterans
AT jonesbobbyl trajectoriesofopioidcoverageafterlongtermopioidtherapyinitiationamonganationalcohortofusveterans
AT williamsjsilas trajectoriesofopioidcoverageafterlongtermopioidtherapyinitiationamonganationalcohortofusveterans
AT martinbradleyc trajectoriesofopioidcoverageafterlongtermopioidtherapyinitiationamonganationalcohortofusveterans